Anämie unter Tripletherapie bei Hepatitis C – Reduktion der Ribavirin-Dosis Mittel der Wahl

• Literatur

• 1 Poordad FF, Lawitz EJ, Reddy KR et al. A randomized trial comparing ribavirin dose reduction versus erythrpoietin for anemia management in prevously untreated patients with cronic hepatitis C receiving boceprevir plus peginterferon/Ribavirin. 47th annual meeting of the European Association for the Study of the Liver (EASL), 18.–23. April 2012 in Barcelona. J Hepatol 2012; 56 (Suppl. 02) Abstract No. 1419